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A B S T R A C T
Aim: A variety of consumer-facing wearables, devices and apps are marketed directly to consumers to detect
atrial fibrillation (AF). However, their management is not defined. Our aim was to explore their role for AF
screening via a survey.
Methods and Results: An anonymous web-based survey was undertaken by 588 health care professionals (HCPs)
(response rate 23.7%). Overall, 57% HCPs currently advise wearables/apps for AF detection in their patients:
this was much higher for electrophysiologists and nurses/allied health professionals (74–75%) than cardiologists
(57%) or other physicians (34–38%). Approximately 46% recommended handheld (portable) single-lead dedi-
cated ECG devices, or, less frequently, wristband ECG monitors with similar differentials between HCPs . Only
10–15% HCPs advised photoplethysmographic wristband monitors or smartphone apps. In over half of the HCP
consultations for AF detected by wearables/apps, the decision to screen was entirely the patient's. About 45% of
HCPs perceive a potential role for AF screening in people aged >65 years or in those with risk factors. Almost
70% of HCPs believed we are not yet ready for mass consumer-initiated screening for AF using wearable devices/
apps, with patient anxiety, risk of false positives and negatives, and risk of anticoagulant-related bleeding
perceived as potential disadvantages, and perceived need for appropriate management pathways.
Conclusions: There is a great potential for appropriate use of consumer-facing wearables/apps for AF screening.
However, it appears that there is a need to better define suitable individuals for screening and an appropriate
mechanism for managing positive results before they can be recommended by HCPs.
1. Introduction
Atrial fibrillation (AF) is the most common sustained arrhythmia
diagnosed in clinical practice, with an incidence that increases in the
elderly [1,2] and a prevalence of diagnosed AF that is progressively
increasing and is expected to further expand in the next decades in view
of progressive aging of the population and exposure to risk factors and
facilitating factors [3,4].
AF is associated with significant morbidity and mortality and is an
important risk factor for ischemic stroke, particularly in the elderly [5].
AF is frequently asymptomatic, particularly in the elderly [6], and
asymptomatic AF is associated with a worse outcome as compared to
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symptomatic AF, both in terms of risk of stroke and mortality [6,7].
Since nearly one in five AF-related ischemic strokes may occur
without a diagnosis of AF prior to the stroke event [8] there is growing
interest in the identification of patients with unrecognized, unknown
asymptomatic AF through screening initiatives [9,10] with consequent
institution of oral anticoagulants in patients at risk. It is well known
that in AF, oral anticoagulation (OAC) is able to reduce the risk of
stroke by more than 60% [11].
Pulse palpation has been the first and simplest method proposed for
AF screening, followed by automatic blood pressure devices with
dedicated algorithms for detecting AF, but more recently several new
methods and tools have been proposed, with an impressive variety of
technologies based on plethysmography or single-lead ECG, also im-
plemented in wearables (smartphones, watches etc.) [12–14]. In 2017 it
was reported that more than 100,000 mobile Health apps and ≥400
wearable activity monitors were available for cardiac rhythm check or
monitoring and that more than 60% of owners of a smartphone use
their phone for information and education about their health [15].
The wide debate focused on benefits, efficacy and limitations of
screening initiatives [16–19] prompted us to propose an on-line survey
to explore current views, current practice and related organizational
issues on AF screening using the most advanced technologies im-
plemented in watches, smartphones and other devices, usually named
“wearables” [20].
Questions in the survey were designed to elucidate how health care
professionals perceive the significance of AF screening through wear-
ables, in what settings it may be considered as appropriate and useful,
what is the current status of referral and what are the potential de-
velopments in the field.
2. Methods
The survey was distributed in two steps. First the invitation to
participate in this anonymous, web-based survey was sent in December
2019 by email to all 177 members of the AF-SCREEN International
Collaboration, a group created in 2016 to promote discussion and re-
search about screening for unknown or under-treated atrial fibrillation
as a way to reduce stroke and death (http://www.afscreen.org/)
[12,21,22]. In January and February 2020, the same invitation was
distributed through e-mails, in two rounds, by AF-SCREEN members to
a “convenience sample” of colleague health care professionals (HCPs),
physicians, nurses or allied health professionals involved in care of
patients with arrhythmias or stroke, including cardiologists, electro-
physiologists, neurologists, internal medicine physicians or geria-
tricians, primary care physicians/general practitioners (PCP/GPs),
nurses, pharmacists or other allied health professionals, as shown in
Table 1. The analysis of the survey was managed in an anonymous way.
Despite anonymity, the question on field of work was answered by 475
respondents: of the 113 respondents who did not answer this question,
23 were members, and 90 were non-members. In this report we will
present numbers and percentages for answers to each of the survey
questions.
3. Results
Overall, 2481 invitations were sent by email and 588 HCPs com-
pleted the survey anonymously (119 AF-SCREEN members and 469
non-members, response rate 23.7%). The geographical region of re-
spondents was reported in 482 replies, and was Europe in 373 (77.4%),
Asia/Oceania in 66 (13.7%) and North or South America in 40 (8.3%),
with 3 (0.6%) in other regions. Survey respondent characteristics are
shown in Table 1.
The first question of the survey analysed if health care professionals
ever advise use by patients of any of the available wearable devices/
apps for AF-detection. The results shown in Fig. 1, panel A indicate that
these devices are never suggested by 43% of respondents, while 57% of
respondents at least sometimes advice their use: handheld (portable)
single-lead dedicated ECG devices in 46% and wristband ECG/EKG
monitors (e.g., Apple Watch 4, Kardia, Huawei, Verily, etc.) in 29%,
with a lower relative percentage of suggestions addressed to wristband
heart rate monitor (e.g., Apple Watch 3, Fitbit, Garmin, Biostrap, etc.)
(15%) or to mobile PPG apps for smartphone camera flash downloaded
from Apple or Google Play stores (10%). There were distinct differences
between groups of health professionals in these responses. Between
62–67% of PCP/GPs, neurologists and other specialist physicians never
advised use of these devices for AF detection compared to 43% of
general cardiologists, and only 25% of electrophysiologists. The figure
was 26% for allied health professionals and nurses, presumably with an
interest in AF screening, and 27% for AF-SCREEN members compared
to 44% for non-members. Similar differentials between HCP categories
were seen for handheld ECGs, and wristband ECGs, with 45% of elec-
trophysiologists sometimes advising wristband ECGs, compared to only
10–20% of other specialists and PCP/GPs.
The second question focused on the scenario(s) where these devices
may have an important role with regard to AF detection (Fig. 1, panel
B) and the answers stress the role of wearables, devices and apps to
search for AF in patients with palpitations or other symptoms but no
previous detected AF (supported by 75% of respondents), as well as for
search of AF post stroke/TIA and post AF ablation with recurrent
symptoms (supported by 48–50% of respondents). Electrophysiologists
were the most likely to advise use of the devices in patients with
symptoms (86%). With regard to the potential use for screening, ac-
cording to 44–46% of respondents there is an important role of this
technology for subjects aged > 65 years or in patients with risk factors
(hypertension, diabetes, etc.). Conversely, screening in less selected
subjects, with lower age, is considered to be meaningful by only a
minority of respondents. Only 10% of HCPs stated there was no value of
any of the potential indications for search of AF or AF screening.
The answers to the question on how frequently HCPs currently have
to deal with subjects with AF detected through wearable devices/apps
reveals that this happens only rarely or occasionally (less than 1–2
times per month) for 25–29% of respondents (Fig. 1, Panel C). Only a
small minority of respondents report to be frequently involved in this
activity, while for 15% no involvement was reported. PCP/GPs were
least likely to have to deal with AF detected this way at least 1–2 times
per month (12%) compared to 30–44% for other physicians and general
cardiologists or electrophysiologists.
The use of wearables or devices for AF search/screening may be
related to a choice taken by the patient or by a physician. According to
respondents to this survey, the use of these devices for AF search was
the patient's personal decision in just over half of cases leading to a
consultation with the HCP, while it was advised by a physician in the
remainder.
The referral to physicians of patients for clinical evaluation after AF
Table 1
Survey respondent field of work (N = 475).
Whole Group AF SCREEN
Members
Non Members
(N = 475) (N = 96) (N = 379)
Category† % % %
Electrophysiologist 37.1 38.6 36.7
General cardiologist 17.7 28.1 15.0










Other 2.9 1 3.4
Legend: Field of work category for respondents.
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detection through wearable devices/apps in more than 50% of cases
was related to patient self-referral or was prompted by a primary care
physicians or, less frequently by other physicians (Fig. 2, panel A). Only
rarely was the referral prompted by pharmacists or patient associa-
tions/groups.
The age of subjects referred to physicians for a clinical evaluation
after AF detection through wearables/apps (Fig. 2, panel B) was in the
majority 65 or older although around 30% were between 55 and 65 and
around 36% below 55.
The organization of referral for clinical evaluation after AF detec-
tion is an important issue and more than half of the respondents
considered as appropriate a referral through general practitioners with
the support of predefined pathways, or through dedicated physicians/
nurses, while conventional contacts were advisable for around 29% of
respondents (Fig. 2, panel C) . Referral from call centres/websites or
through pharmacists had a low rate of preferences.
The potential disadvantages of mass community screening using
wearable devices/apps were reported as related to anxiety in people
with a positive test by around 65% of respondents, but were also related
to false reassurance in case of a negative test by 41% of respondents
(Fig. 3, panel A). Moreover, for 39% of respondents the risk of bleeding
due to anticoagulant prescriptions after a positive test, in light of a still
Fig. 1. Questions and answers of the survey on use of wearable devices/apps for AF detection.
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unproven benefit for AF detected this way, actually represents a dis-
advantage of screening. Conversely, for around 20% of respondents no
important disadvantages for mass community screening are currently
perceived at the level of individual people.
As there are now many Apps currently available for download from
Apple or Google Play stores, between 30 and 45% of respondent con-
sidered in order to appropriately guide the consumers it would be im-
portant to obtain validation through randomized controlled trials, re-
ports based on scientific data, or recommendations from Scientific
Associations. About 25% believed there should be more rigorous reg-
ulation from Health Authorities and/or valid comparisons between
devices or apps (Fig. 3, panel B).
The final question of the survey explored respondents’ thoughts on
whether we are actually ready to commence mass community screening
for AF using wearable devices/apps now: the answer was no for almost
70% of respondents. There were no important differences amongst the
different HCPs.
4. Discussion
Wearables now allow non-invasive monitoring of a range of human
body vital signs and could facilitate user-initiated disclosure of many
Fig. 2. Questions and answers of the survey on referral of patients after AF detection through wearable devices/apps.
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diseases [23]. The field of mobile technology has in recent years been
characterized by an impressive growth which has the potential for
changing clinical practice as a disruptive transformation. Moreover, the
use of wearables to diagnose AF is being promoted widely to the general
public by manufacturers as a health benefit of their products. However,
apart from the need for specific regulations, also taking into account the
legal implications of mode and time of physician's reaction to detection
of a suspected AF [24,25], our survey respondents did convey a number
of caveats on the use of wearables and Apps. Finally, the majority in-
dicated that these devices were not yet ready for commencing mass
screening for AF.
In general, screening for an arrhythmia like AF using devices and
apps marketed to the general community should be well organized,
with a specific and appropriate design of screening initiatives, as well as
defined pathways involving health care professionals and individuals
engaged in the screening process with effective feedback loops [26]. For
AF, the wide diffusion of devices that can provide information on car-
diac rhythm carries the risk that the coordination, in terms of appro-
priate targeting and management of screening activities, may no longer
be in the hands of clinicians and HCPs, but will by default become an
uncontrolled activity, with unknown risks and consequences
[20,27,28].
Our survey focused on wearables and apps [25] in the setting of
screening and search for AF, and highlights that in a sample of almost
600 HCPs, involving mostly electrophysiologists, cardiologists and
general practitioners, the use of these devices is currently advised by
around half of them. Unsurprisingly, electrophysiologists and to a lesser
degree general cardiologists, were more likely to advise their use that
other specialist physicians and PCP/GPs. The nurses and allied health
professionals who took our survey were also high users of this tech-
nology, as might be expected for groups of these HCPs with an interest
in AF screening who were recruited to this survey. Overall, there was a
preference for handheld (portable) single-lead dedicated ECG devices
and to a slightly lesser degree for wristband ECG monitors, but a much
lower degree of preference for apps based on photo-plethysmography
using a wristband or the camera flash of smartphones. This may be
interpreted as a higher degree of confidence, from the perspective of
physicians, on tools detecting AF by direct recording of an electro-
cardiographic signal.
Most of the consumer-facing devices and apps are registered as a
medical device [29–34]. Many studies have validated the novel devices
and tools, with variable sensitivity and specificity. However, the same
rigorous validation does not necessarily apply to many apps proposed to
consumers without availability of valid scientific data [15], nor to the
outcome of screen-detected AF in the mostly younger people who
choose to buy and use wearable devices and apps in this way. In the
literature, a great debate has developed in recent years on the sig-
nificance and effectiveness of initiatives targeting AF search/screening
in specific target populations. Moreover, many wearable products are
marketed as direct-to consumer so it is probable that they will be lar-
gely used by subjects with healthier profiles and lifestyle [35], as seen
in both the Apple Heart Study and Huawei Heart Study where the mean
age was 41 and 35, respectively [33,34]. These individuals have a low
pre-test probability of AF with a questionable significance of screening
for AF [12]. In fact, the “possible AF” notification rate in the 52% of
participants aged <40 in the Apple Heart Study was only 0.16% [34].
Fig. 3. Questions and answers of the survey on AF screening using wearable devices/apps.
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As a matter of fact, age- and literacy-related disparities in the use of
mobile technologies were reported both in Germany [36] and the
United States [37], with a discrepancy between the epidemiology of AF,
more common and more dangerous among older people with multiple
chronic diseases, and the low penetration in this population of wearable
devices [38].
Our survey suggests that there is a consensus on recommending
wearables/apps for searching for AF in symptomatic patients or post
stroke/TIA, two settings where wearables may constitute an alternative
to Holter monitoring (24-h or longer durations), external continuous or
loop recorders or, even to implantable loop recorders. The place of AF
screening itself, whether this is case finding, or opportunistic or sys-
tematic screening is still a debated topic [12,16,17,39–44]. Thus, it is
not surprising that the use of wearables/Apps for this purpose remains
even more controversial. What emerges from the current referral of
subjects following AF detection by wearables and apps marketed di-
rectly to consumers is a true asymmetry between the current buyers and
users of wearables, and the appropriate target. Buyers and wearers are
mostly people younger than 50 years, and not those who would re-
present the most appropriate age group to target with AF screening
programmes according to detection rates and number needed to screen
to detect one person requiring thromboprophylaxis for stroke [10], as
recommended in guidelines and consensus documents (i.e. subjects
above 65–75 years) [12–14,45–47].
At present, despite the availability of many wearables for mon-
itoring cardiac rhythm and detecting AF, it is apparent from our survey,
that the evaluation by physicians of patients with AF detected through a
wearable device is not common, and that there are no specifically-de-
fined care pathways for referral, despite general recommendations
[12–14,45,46].
According to around 65% of the respondents, the potential anxiety
of people who tested positive at AF screening constitutes a major lim-
itation to the use of wearables, and this concern, including also the risks
of false positives, and of prescribing anticoagulation to those who may
not benefit but are exposed only to the risks, similar to any disease
screening initiative, is in line with the comments by US Preventive
Services Task Force and other experts in the field [16,17,40]. However,
appropriate targeting with screening addressed to subjects at a higher
risk of stroke if AF is detected, coupled with detailed information to
screening candidates on the significance and the implications (in terms
of anticoagulant treatment) of undergoing screening, could help to
minimize anxiety, as in any screening program. Importantly, perceived
disadvantages also included the risks of falsely reassuring those with AF
that may be missed by the various wearable systems that rely on in-
termittent-monitoring PPG algorithms to initiate a warning. The het-
erogeneous opinions on the current value and significance of AF
screening through wearables is highlighted by the opposite position of
20% of respondents, who actually indicated that nowadays there are no
important disadvantages at the individual level for promoting mass
community screening activities.
Ongoing randomized studies, already started or in a planning phase
[12,14,41] will be an important step for defining the net benefit of AF
screening in specific populations, with regard to stroke prevention and
long-term survival, against adverse bleeding events related to OAC
[48,49]. As compared to other screening initiatives, AF screening
through wearables certainly has potential, provided there is appropriate
population targeting, for a favourable cost-effectiveness profile, a key
element in evaluation of health care interventions [50]. The collection
of data on population screening, in specific target populations, can help
to estimate the benefits of screening interventions, as done in Sweden
where the 5-year follow up of a systematic screening performed in
patients aged 75 showed a lower incidence of ischemic stroke in the
intervention region, as compared with a control region, in parallel with
an 88% rate of screening-detected AF treatment with oral antic-
oagulants and excellent long term adherence to therapy [51].
For some wearables, the diagnostic value of the specific technology
has been tested in terms of sensitivity and specificity (Huawei, Apple
watch, Kardia, etc.) in specific settings, with some limitations given the
ultimately small numbers used in the direct comparisons. However, as
highlighted by respondents, there is absolute need to make clear to
consumers what devices or Apps are validated. In the rapidly growing
market of mobile health technology (more than 100,000 mobile Health
apps and ≥400 wearable activity monitors available) [15], no clinical
validation is available for many of these devices and therefore caution
is needed in their use for clinical reasons. Given this perspective, sci-
entific associations, patient associations and regulatory agencies should
provide some guidance on how to organize initiatives on AF screening
and in whom it is reasonable to address a search for AF, as well as
propose pathways for appropriate evaluation of subjects who test po-
sitive, independently of commercial interests. Even if there is a general
tendency in the market to directly approach consumers and to promote
use of wearables and Apps without the traditional control of physicians,
the need for appropriate targeting, provision of information, and eva-
luation of individuals tested positive, indicate that physicians should be
involved in these activities. This is required to magnify the potential
value of these new diagnostic resources that may actually change the
process of care, and minimize the harms of inappropriate use. Despite
general recognition of the potential, it is noteworthy that according to
around 70% of HCPs we surveyed, we are actually not ready to apply
the technology of wearable devices/apps for mass community AF
screening.
In our society the media share important responsibilities in ad-
dressing the general use of wearables in a proper and rational way, with
need for a clear distinction with regard to lifestyle and wellness, the
fields where wearables are widely promoted [27]. Scientific Associa-
tions, patient groups and associations, general practitioners, specialist
physicians, and researchers in the field, as well as the industry, other
health care providers and regulators should have a greater dialog and
collaboration in the field of AF screening to increase the value for the
health care process through appropriate use of these new diagnostic
resources, in a context where physicians responsibilities still need to be
well defined.
Our survey has some limitations, first of all related to a response
rate of 24% . Response rates to physician surveys have declined over the
past several decades, and paradoxically web surveys were found to
result in lower response rates compared to other more traditional data
collection modalities [52,53]. As reported in the literature, conducting
surveys among physicians and medical personnel is more difficult than
in other fields, and response rates are actually lower than response rates
of surveys conducted within the general population [52-54].
Moreover, as for any anonymous survey based on voluntary parti-
cipation, we can presume that willingness to participate may per se
identify health care professionals with a specific interest on the topic of
AF screening and with specific knowledge on most recent technologies
for cardiac rhythm monitoring. On the one hand this may limit the
possibility to extrapolate the findings to other health care professionals
with a lower degree of knowledge or confidence with wearables, but on
the other hand it increases the relevance of the caution in promoting
mass screening for AF using wearables that this survey highlights.
5. Conclusions
There is a great potential for appropriate use of consumer-facing
wearables/apps for AF screening, but the current consumer-led use
following direct marketing suggests the need for identification of ap-
propriate targets, organization of referral and appropriate patient in-
formation on the purpose and implications of AF detection. Greater
dialog between stakeholders is required to ensure there is value for the
health care process through appropriate use of these new diagnostic
resources. The final gestalt of the majority of the 588 respondents to our
survey was that these apps and devices which are directly marketed to
consumers are not yet ready for mass screening for AF.
G. Boriani, et al. European Journal of Internal Medicine 82 (2020) 97–104
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